Articles tagged with Bleeding
A team of researchers from Texas A&M University has developed an injectable bandage using a gelling agent commonly used in pastries, which can stop bleeding and promote wound healing. The injectable hydrogels are made with kappa-carrageenan and nanosilicates to form a controlled release of therapeutics.
The experimental drug andexanet has been shown to control serious bleeding in patients taking Factor Xa inhibitors. The study found that andexanet rapidly reversed the anticoagulant effect of these drugs without significant safety problems, achieving clinical hemostasis in 83% of patients.
Patients treated with dabigatran had a 28% lower risk of major cardiovascular complications compared to those receiving a placebo. Dabigatran also showed significant benefits in reducing the risk of specific events such as heart attack, stroke and blood clots.
A new study found that using genetic information to inform drug choice reduced adverse events by 42 percent in patients with acute coronary syndrome. Genetic testing led to different prescribing patterns, including more frequent use of prasugrel and ticagrelor.
In a trial of over 3,800 patients treated for STEMI at more than 180 centers, researchers found that ticagrelor is safe to use in combination with clot busters in patients younger than 75. The study met its primary endpoint indicating no difference in major bleeding rates between ticagrelor and clopidogrel.
Scientists from ITMO University have developed a new treatment for internal bleeding using magnetically-driven nanoparticles containing thrombin. The treatment reduces overall blood loss by 15 times and accelerates local clot formation.
A study presented at the ARRS 2018 Annual Meeting found that emergency patients are often given unnecessary head CT scans, leading to radiation exposure and healthcare costs. Motor vehicle accidents were associated with a higher rate of non-indicated CT examinations.
A Phase 2 clinical trial shows that patients with acute ischemic stroke can safely tolerate high doses of 3K3A-APC, a promising anti-stroke drug. The treatment also substantially reduced cerebral hemorrhage in patients.
Biomedical engineers developed a miniaturized system mimicking blood vessel injury, allowing for the study of bleeding and clotting. The device replicates all aspects of blood vessel injury, including clot formation and repair, and responds to drugs and other alterations.
A review of clinical data from trials and observational studies suggests that prasugrel and ticagrelor reduce major adverse cardiac events compared to clopidogrel, but with increased bleeding risk. Prasugrel shows superior benefits in STEMI patients
A study published in Mayo Clinic Proceedings reports significant improvements in HHT patients with severe bleeding treated with intravenous bevacizumab. The treatment reduced nose and gastrointestinal bleeds, allowing patients to stop or reduce blood transfusions, improving quality of life.
More than 2,000 maternal-fetal medicine specialists will present research on preventing postpartum hemorrhage, reducing cesarean births, and treating opioid misuse during pregnancy. The Society for Maternal-Fetal Medicine's annual meeting in Dallas aims to reduce high-risk pregnancy complications and promote public policy advancements.
Researchers found that tranexamic acid prevents blood loss after vaginal births and postpartum hemorrhage among women with operative vaginal deliveries or episiotomies. The study, presented at the Society for Maternal-Fetal Medicine's annual meeting, suggests TXA should be considered for women at risk of PPH.
Spontaneous subarachnoid hemorrhage is a rare type of stroke occurring in 6% of pregnant women, with better outcomes compared to non-pregnant women. Pregnant women with sSAH have lower mortality rates and are more likely to be discharged home.
Researchers at the University of Edinburgh identified a key protein driving repair of the womb lining during menstruation, which is reduced in women with heavy periods. Boosting levels of this protein shows promise as a novel, non-hormonal treatment to reduce blood loss and improve tissue repair.
Researchers have measured and mapped the key molecular forces on platelets that trigger blood clotting. The findings suggest that platelets care about the direction of forces applied to them, requiring a lateral force signal to prevent unnecessary clotting.
A groundbreaking gene therapy trial has shown that over one year on from a single treatment, participants with haemophilia A are showing normal levels of the previously missing protein, effectively curing them. The results have particular significance as the first successful gene therapy trial for the haemophilia A.
A new therapeutic paradox targets thrombo-vascular complications in kidney disease by boosting a regulatory protein called STUB1, which interacts with tissue factor to trigger clotting. This approach may offer an alternative to standard heparin treatment while maintaining a balance between pro-clotting and anticoagulant factors.
A genetic mutation in an extended Amish family in Indiana has been discovered to protect against multiple aspects of biological aging in humans. The mutation results in longer telomeres, lower fasting insulin levels, and reduced diabetes risk.
A new tool, the Ottawa Subarachnoid Hemorrhage Rule, helps identify high-risk patients with potentially fatal brain aneurysms, reducing wait times and unnecessary testing. The rule has been validated in over 1153 patients, showing it can improve survival rates and save lives.
A study of middle-aged adults found that functional impairment was common among the cohort and often progressed to further physical decline or death over a 10-year follow-up. The findings challenge the notion that functional impairment is temporary in middle age and suggest a need for early intervention.
Researchers at Rosalind Franklin University are investigating a new approach to treating patients with both severe bleeding and traumatic brain injury (TBI). The study aims to find a way to stabilize patients with vasopressin or similar compounds, while maintaining blood flow to vital organs.
A new study found that treatment with tranexamic acid must be given within minutes of severe bleeding to improve survival by 70%. The World Health Organization has updated its recommendations for the use of tranexamic acid, calling for it to be made readily available in all health systems to reduce global deaths from severe bleeding.
A meta-analysis of over 40,000 patients found that the likelihood of death due to blood loss was reduced by over 70% if the low-cost drug was given immediately after injury or birth. The survival benefit rose to 70% if treatment was administered promptly, with a 10% decrease in survival benefit for every 15-minute delay.
The SENIOR trial found that a Synergy bioabsorbable polymer DES with shorter dual antiplatelet therapy (DAPT) is more effective than a bare-metal stent in elderly patients. This new strategy reduces adverse events without increasing bleeding risk, suggesting a change in recommended PCI strategies for this age group.
A $10 microchip can be mounted onto a traditional ultrasound probe, providing 3-D imaging abilities similar to CT scans or MRIs. This technology has the potential to improve patient care, especially in emergency medicine and trauma cases where CT scans are not available.
A large observational study compared the safety of new anti-clotting drugs with warfarin. The results show that DOACs are not associated with a higher risk of major bleeding, similar to warfarin. This suggests that DOACs can be a viable alternative for treating serious blood clots.
A recent presentation highlights the need for individualized assessment based on patient characteristics and risk factors to diagnose postmenopausal bleeding. The standard diagnostic approach has changed over the past 25 years, but no single method is suitable for all patients.
Patients with nonvalvular atrial fibrillation using non-vitamin K oral anticoagulants (NOACs) may be at increased risk of major bleeding when combined with certain medications that share metabolic pathways. Concurrent use of amiodarone, fluconazole, rifampin, and phenytoin significantly increases the incidence rate of major bleeding.
A new study found that customizing warfarin dosing to a patient's genetic and clinical profile reduces adverse outcomes compared to clinically-guided dosing. The study involved 1,650 patients undergoing hip or knee replacement, who were randomly assigned to either genotype-guided or clinically-guided dosing.
Researchers found that injecting interleukin-27 (IL-27) into mice after a hemorrhagic stroke helped them recover and had less brain damage. IL-27 may play a critical role in protecting the brain from stroke-induced damage, offering new avenues for stroke treatment strategies.
Three people were treated for serious eye injuries after being shot with Nerf guns, including a child who developed swelling in the cornea and retina. Doctors urge parents to consider protective eyewear when allowing children to play with these guns.
The CHANGE-DAPT trial found that following contemporary guidelines for dual anti-platelet therapy may not be preferable to older guidelines in reducing ischemic events, but increases major bleeding risk. Newer-generation drug-eluting stents have shifted the risk-benefit balance of ticagrelor in ACS patients undergoing PCI.
A new study published at ESC Congress shows that blood pressure variability is strongly associated with adverse outcomes in patients with atrial fibrillation. The study found that consistency in blood pressure control is vital, regardless of patient age or blood pressure level.
The EMANATE trial shows that apixaban lowers stroke risk in anticoagulation-naïve patients with atrial fibrillation scheduled for elective cardioversion. Patients treated with apixaban had fewer strokes than those receiving usual care, with similar bleeding rates to warfarin.
The COMPASS trial found that combining rivaroxaban and aspirin improved survival by 18% and reduced cardiovascular death, stroke, or heart attack by 24%. The treatment also increased bleeding risk but showed significant net benefits for patients.
A new study found that using two anticlotting medicines instead of three can reduce the risk of major bleeding in patients with atrial fibrillation who have had a stent placed. The RE-DUAL PCI trial showed that dabigatran, combined with either clopidogrel or ticagrelor, cut the risk of bleeding by half compared to standard triple therapy.
The ESC Focused Update provides recommendations for dual antiplatelet therapy (DAPT) in patients with coronary artery disease. DAPT reduces the risk of acute to very late stent thrombosis, but the optimal duration is uncertain. The Task Force recommends a personalized approach based on ischaemic versus bleeding risks.
The von Willebrand factor molecule undergoes a two-step transformation to activate blood clotting in response to changes in blood flow, which can help prevent hemorrhage or life-threatening blood clots. The findings could inspire smart drugs that target only diseased areas of the body, reducing the risk of excessive bleeding.
Researchers from Kumamoto University found that different anticoagulants can form thrombi at varying rates, with some having faster clotting times than others. This study used a Total Thrombus-Formation Analysis System to analyze blood samples from patients taking warfarin or direct oral anticoagulants.
Subarachnoid hemorrhages account for 5-10% of all strokes, particularly among younger patients, and can result in long-term neuropsychological effects. Expert treatment is crucial, with high-volume centers and specialized neurosurgeons offering the best outcomes.
A meta-analysis of randomized-clinical trials found that full-dose bivalirudin infusion post-PCI for four hours is associated with improved net adverse clinical events and all-cause mortality. Bivalirudin exhibits a lower risk of bleeding compared to unfractionated heparin, but also increases the risk of acute stent thrombosis.
Researchers at DGIST have identified a thermally responsive elastin-like polypeptide that controls acute intracerebral hemorrhage by forming protein nanostructures in damaged cerebral blood vessels. The polypeptide also accelerates vascular restoration and stimulates brain tissue regeneration.
A new scoring method developed by researchers can help identify individuals at high risk of serious bleeding after a stroke. The score is based on ten factors, including age, sex, smoking, and prior strokes, and ranges from 2% for low-risk individuals to over 10% for those aged 75-85 with multiple risk factors.
The authors emphasize the need for a life course approach to address vaginal bleeding needs of girls and women across their lives. The lack of open discussion and access to clean water, sanitation, and factual information hinder effective management of bleeding, leading to anaemia and other health issues.
A study by Columbia University's Mailman School of Public Health highlights the dangers of vaginal bleeding taboos in low-income countries, where limited access to clean water and sanitation exacerbates the issue. The researchers emphasize the need for a comprehensive approach addressing vaginal bleeding across the life course.
A study of 53 hospitals found certain management practices in labor and delivery units associated with higher cesarean delivery rates and maternal complications. Women receiving care at hospitals with proactive unit culture management had a higher risk of cesarean delivery, postpartum hemorrhage, and prolonged hospital length of stay.
A new therapy, idarucizumab, has been shown to rapidly reverse the effects of the blood thinner dabigatran in patients with life-threatening bleeding or emergency surgery needs. The study found that idarucizumab was able to stop bleeding within 2.5 hours and allow surgery to begin at a median of 1.6 hours after administration.
A study of nearly 130 adolescent and young women with sports-related concussions found an association between concussion and abnormal menstrual bleeding patterns. The researchers observed a higher incidence of irregular bleeding among those with concussions compared to non-injured controls.
Long-term daily aspirin use increases risk of disabling or fatal bleeding in people aged 75 or over. Co-prescribing proton-pump inhibitors can reduce this risk by up to 90%. Studies have shown that the benefits of long-term PPI use outweigh the risks for patients in this age group.
Researchers have designed a safer antiplatelet drug based on a snake venom protein that interacts with platelets to form blood clots. The new study found that the molecule prevented platelet clotting and slowed down blood clot formation in mice, without increasing bleeding risk.
Researchers have discovered a previously unknown cell receptor interaction that can safely prevent blood clots. The new mechanism targets the Mac-1-GPIbα receptor duo, which is required for harmful clots, but blocking its interaction with a therapeutic small molecule has no effect on bleeding risk.
A study published in Neurology found that hospitals transitioned people with strokes to early comfort care at varying rates, ranging from 0.6% to 37.6%. Factors such as age, sex, and stroke type influenced these decisions. The study highlights the need for better understanding of how these transitions are made.
The TOPIC study found that switching from a new P2Y12 inhibitor plus aspirin to maintenance DAPT with aspirin plus clopidogrel one month after acute coronary syndrome (ACS) significantly reduced bleeding risk, with a 70% lower rate of major bleeding events. Ischemic events remained similar between the two regimens.
Patients with new-onset atrial fibrillation post-TAVR have a nearly five-fold greater risk of early stroke compared to those without AF. The BRAVO-3 trial found that patients with existing or new AF had higher rates of pre-existing comorbidities and were more likely to receive oral anticoagulants.
A study published by the American College of Surgeons found that 93.79% of trained surgeons believe teaching bleeding control techniques to the public is an appropriate priority. The study's findings suggest that training surgeons can effectively disseminate bleeding control knowledge and teach skills to the general public.
A global trial of 20,000 women in 21 countries found that tranexamic acid reduces death due to bleeding after childbirth by a third if given within 3 hours. The drug is inexpensive and widely available, making it a promising solution for preventing maternal deaths in low-income countries.
A global trial found that administering tranexamic acid within three hours of giving birth reduced death due to bleeding by 31%, with no side effects. The study also showed a significant reduction in the need for urgent surgery, saving up to 36% of mothers' lives.
A unique bleeding syndrome associated with chronic gastrointestinal bleeding has been identified by researchers at MUSC. The syndrome, characterized by acute bleeding and presence of iron deficiency anemia, is recognized as a common condition that practicing physicians should be aware of.
The pivotal MOMENTUM 3 trial found that patients with the new HeartMate 3 LVAS experienced fewer adverse clotting and bleeding events than those with the control device, HeartMate II. The study also developed a novel scoring system to quantify these events.